Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia
  • Christel van Dongen
    Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands
  • Marlou Janssen
    Department of Pulmonary Medicine, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands
  • Robrecht van der Horst
    Department of Pulmonary Medicine, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands; Department of Intensive Care Medicine, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands
  • Dave van Kraaij
    Department of Cardiology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands
  • Ralph Peeters
    Department of Rheumatology, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands
  • Leon van den Toorn
    Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
  • Remy Mostard
    Department of Pulmonary Medicine, Zuyderland Medical Center, Heerlen-Sittard, the Netherlands

Keywords

COVID-19, coagulopathy, microvascular damage, pulmonary hypertension, right ventricular failure

Abstract

COVID-19 is a novel viral disease caused by SARS-CoV-2. The mid- and long-term outcomes have not yet been determined. COVID-19 infection is increasingly being associated with systemic and multi-organ involvement, encompassing cytokine release syndrome and thromboembolic, vascular and cardiac events. The patient described experienced unusually rapid development of pulmonary hypertension (PH) and right ventricular failure after recent severe COVID-19 pneumonia with cytokine release syndrome, which initially was successfully treated with methylprednisolone and tocilizumab. The development of pulmonary hypertension and right ventricular failure – in the absence of emboli on multiple CT angiograms – was most likely caused by progressive pulmonary parenchymal abnormalities combined with microvascular damage of the pulmonary arteries (group III and IV pulmonary hypertension, respectively). To the best of our knowledge, these complications have not previously been described and therefore awareness of PH as a complication of COVID-19 is warranted.

VIEW THE ENTIRE ARTICLE

References

  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034.

  • Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7(6):e438–e440.

  • Wu J, Pan J, Teng D, Xu X, Feng J, Chen YC. Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia. Eur Radiol 2020 May 4;1–8. doi: 10.1007/s00330-020-06915-5 [Epub ahead of print].

  • Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–147.

  • Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020;220:1–13.

  • Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020 May 21. doi: 10.1056/NEJMoa2015432 [Epub ahead of print].

  • McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020 May 7. doi: 10.1016/S2665-9913(20)30121-1 [Epub ahead of print].

  • Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53(1):1801913.

    • Views: 8278
    HTML downloads: 409
    PDF downloads: 1574

    Published: 2020-06-17
    Issue: 2020: Vol 7 No 7 (view)

    How to cite:
    1.
    Dongen C van, Janssen M, van der Horst R, van Kraaij D, Peeters R, van den Toorn L, Mostard R. Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia. EJCRIM 2020;7 doi:10.12890/2020_001784.